- In April 2023, MTF Biologics, a leading nonprofit organization dedicated to providing high-quality allografts, announced the launch of a next-generation machined bone allograft designed to support complex spinal fusion procedures. This innovation leverages advanced processing techniques to improve graft integration and structural integrity, catering to the rising demand for biologically enhanced solutions. The development reflects MTF Biologics’ commitment to advancing spinal care through precision-engineered allograft products that promote optimal patient outcomes
- In March 2023, Orthofix Medical Inc. received FDA clearance for its expanded line of Trinity Elite® allograft solutions. The new formulation combines viable cells with a demineralized bone matrix, enhancing osteoinductivity and improving fusion potential. This milestone strengthens Orthofix’s position in the biologics segment, offering spine surgeons more reliable and regenerative options for spinal fusion surgeries in both minimally invasive and open approaches
- In February 2023, RTI Surgical Holdings, Inc. announced a strategic collaboration with a prominent academic research institution to explore the next generation of demineralized bone matrix (DBM) formulations tailored for spinal applications. The partnership aims to combine clinical expertise with material science innovations to enhance graft performance, thereby supporting RTI’s goal of delivering high-quality, evidence-based allograft solutions for spine care
- In February 2023, AlloSource introduced ProChondrix CR, a cryopreserved osteochondral allograft designed to restore cartilage and support spinal load-bearing surfaces. Though primarily used in orthopedic repair, this innovation is being adapted for spinal procedures requiring biologically active surfaces. The product exemplifies AlloSource’s broader mission to extend the benefits of living tissue allografts to the spinal sector, offering new pathways for patient recovery
- In January 2023, Xtant Medical Holdings, Inc. launched its Fortilink-TS line of interbody implants integrated with cancellous bone allografts. These implants are designed for thoracolumbar spinal fusion procedures, enhancing structural support and biological healing. The launch represents Xtant’s continued focus on combining hardware and biologics to deliver comprehensive solutions for complex spine conditions, aligning with the growing preference for biologically active implant systems.
